We recently reported on a trial that compared the effects of twice yearly injections of alemtuzumab versus interferon beta-1a. The results showed that alemtuzumab was superior to interferon in reducing the progression of disability.
In the current study, investigators of the CARE MS II trial re-analysed the trial data with a more comprehensive set of disability measures, such as tests of hand functions, walking, and visual assessments. They found that over the course of the study, 28% of those taking alemtuzumab showed at least a one point improvement in disability measures (EDSS) compared with 15% of those taking interferon beta-1a suggesting that alemtuzumab can reduce, and to some extent reverse, the disability in people with relapsing-remitting MS as compared to interferon beta-1a.
This study further shows the effectiveness of alemtuzumab in people with relapsing-remitting MS.
Read the full article (external website opens in a new window)